HomeCompareNTP vs MRK

NTP vs MRK: Dividend Comparison 2026

NTP yields 227.12% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NTP wins by $60.1K in total portfolio value
10 years
NTP
NTP
● Live price
227.12%
Share price
$4.22
Annual div
$9.57
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$90.8K
Annual income
$102.29
Full NTP calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — NTP vs MRK

📍 NTP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNTPMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NTP + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NTP pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NTP
Annual income on $10K today (after 15% tax)
$19,305.04/yr
After 10yr DRIP, annual income (after tax)
$86.95/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, MRK beats the other by $720.80/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NTP + MRK for your $10,000?

NTP: 50%MRK: 50%
100% MRK50/50100% NTP
Portfolio after 10yr
$60.8K
Annual income
$526.29/yr
Blended yield
0.87%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

NTP
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NTP buys
0
MRK buys
0
No recent congressional trades found for NTP or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNTPMRK
Forward yield227.12%3.25%
Annual dividend / share$9.57$3.08
Payout ratio50%42%
1-year div growth0%5.5%
5-year div CAGR-50%8.2%
Portfolio after 10y$90.8K$30.7K
Annual income after 10y$102.29$950.29
Total dividends collected$43.3K$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NTP vs MRK ($10,000, DRIP)

YearNTP PortfolioNTP Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$22,056$11,355.91$11,192$351.54+$10.9KNTP
2$35,304$11,703.97$12,524$392.70+$22.8KNTP
3$46,529$8,754.18$14,015$438.65+$32.5KNTP
4$55,178$5,391.46$15,682$489.96+$39.5KNTP
5$62,028$2,987.66$17,547$547.23+$44.5KNTP
6$67,939$1,569.42$19,632$611.16+$48.3KNTP
7$73,498$803.27$21,963$682.53+$51.5KNTP
8$79,049$406.07$24,571$762.18+$54.5KNTP
9$84,787$204.08$27,486$851.08+$57.3KNTP
10$90,824$102.29$30,745$950.29+$60.1KNTP

NTP vs MRK: Complete Analysis 2026

NTPStock

Nam Tai Property Inc., through its subsidiaries, owns, develops, and operates technology parks in the People's Republic of China. It focuses on redeveloping three parcels of land in Gushu and Guangming, Shenzhen into technology parks, as well as rents properties. The company was formerly known as Nam Tai Electronics, Inc. and changed its name to Nam Tai Property Inc. in April 2014. Nam Tai Property Inc. was founded in 1975 and is headquartered in Shenzhen, the People's Republic of China.

Full NTP Calculator →

MRKHealthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this NTP vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NTP vs SCHDNTP vs JEPINTP vs ONTP vs KONTP vs MAINNTP vs JNJNTP vs ABBVNTP vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.